Title | Journal | Journal Categories | Citations | Publication Date |
---|---|---|---|---|
Treatment Characteristics and Real-World Progression-Free Survival in Patients with Unresectable Stage III NSCLC who Received Durvalumab After Chemoradiotherapy: Findings from the PACIFIC-R Study | 2022 | |||
Mutace u nádorových onemocnění | 2018 | |||
ESMO Clinical Practice Guidelines for diagnosis, treatment and and folow-up | 2020 | |||
10.14735/amko20154S28 | ||||
10.1016/S1470-2045(20)30539-8 |